PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32537715-3	2020	The primary objective of this study was to evaluate the effects of repeated doses of fedratinib on the activity of CYP2D6, CYP2C19, and CYP3A4 in patients with solid tumors using a CYP probe cocktail.	Fedratinib	85-95	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	123-130	
32537715-8	2020	CONCLUSION: Fedratinib is a weak inhibitor of CYP2D6, and a moderate inhibitor of CYP2C19 and CYP3A4.	Fedratinib	12-22	cytochrome P450 family 2 subfamily C member 19	Homo sapiens	82-89